The double upgrade from Truist, combined with upward EPS revisions and a near-term earnings catalyst, provides a bullish setup, but the high short interest and average firm accuracy warrant caution. Traders should consider initiating a long position with a stop below the prior PT of $190, targeting the $235 level, and be prepared for elevated volatility around the July 29 earnings release.
Price Chart
Executive Summary
Truist Securities double-upgraded Biogen (BIIB) from Hold to Buy on July 13, raising the price target to $235 from $190, a 23.7% increase. The current price is $199.15, implying 18% upside to the new target. Truist has a 55% accuracy rate on 3,790 calls with an average return of 3.1%, placing it in the middle tier among analysts covering BIIB. Consensus is 63.6% Buy (28 of 44 analysts), 34.1% Hold, and 2.3% Sell, with a mean target of $222.83 and a median of $221. The new PT of $235 sits above both the mean and median. The upgrade is the only analyst action in the past 30 days, with no downgrades, and EPS revisions for the current quarter are trending up. Earnings are due on July 29, just 16 days away, adding a catalyst timing element. High short interest of 61% and mixed institutional signals create a divergence between bearish positioning and this bullish call.
Impact Score
Consensus & Targets
Of 44 analysts covering BIIB, 9 rate it Strong Buy, 19 Buy, 15 Hold, 1 Sell, and 0 Strong Sell — a 63.6% Buy, 34.1% Hold, 2.3% Sell split. The consensus is clearly bullish, with Truist's upgrade aligning with the majority but moving from a more cautious stance.
The mean price target is $222.83, median $221, high $300, and low $157. At $199.15, the current price implies 11.9% upside to the mean. Truist's new PT of $235 is 5.5% above the mean and 6.3% above the median, placing it in the top quartile of targets.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-13 | Truist Securities | upgrade | Buy | $235.00 |
| 2026-07-08 | Morgan Stanley | maintain | Equal-Weight | — |
| 2026-07-07 | RBC Capital | maintain | Outperform | $242.00 |
| 2026-06-29 | Needham | maintain | Buy | $256.00 |
| 2026-06-18 | Morgan Stanley | maintain | Equal-Weight | $224.00 |
| 2026-06-15 | Mizuho | maintain | Outperform | $221.00 |
| 2026-06-08 | Needham | upgrade | Buy | $255.00 |
| 2026-05-27 | RBC Capital | maintain | Outperform | $227.00 |
| 2026-05-15 | Piper Sandler | reiterate | Overweight | $225.00 |
| 2026-05-01 | Citigroup | maintain | Neutral | $200.00 |
In the past 30 days, there has been 1 upgrade (Truist) and 0 downgrades for BIIB. EPS revisions show a mixed picture: the current quarter estimate was revised up once in the last 30 days, while the current fiscal year estimate had one downward revision. However, next quarter and next year estimates both saw upward revisions (1 and 2 respectively), suggesting improving near-term outlook.
Firm Track Record — Truist Securities
Truist Securities accuracy: 55% on 3790 calls | avg return: 3.1%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 13% | top tier |
| Morgan Stanley | 83% | 5/6 | 5.5% | top tier |
| Piper Sandler | 71% | 5/7 | 1.6% | top tier |
| Wedbush | 67% | 4/6 | 2.1% | top tier |
| JP Morgan | 67% | 2/3 | 2.5% | top tier |
| HC Wainwright & Co. | 57% | 4/7 | 1.4% | above average |
| UBS | 50% | 1/2 | 0.6% | below average |
| Barclays | 50% | 2/4 | -2.8% | below average |
| Canaccord Genuity | 50% | 1/2 | -2.1% | below average |
| Goldman Sachs | 50% | 1/2 | -0.1% | below average |
Truist Securities has a 55% accuracy rate on 3,790 rated calls, generating an average return of 3.1%. Among firms covering BIIB, Jefferies (100% on 2 calls), Morgan Stanley (83% on 6), and Piper Sandler (71% on 7) are top performers. Truist's accuracy is below these top-tier firms but above the worst performers like Mizuho (33% on 3) and Oppenheimer (33% on 3). This upgrade is a contrarian move relative to Truist's own prior Hold rating, but not from a top-accuracy firm.
Earnings Estimates
Next earnings: Jul 29, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $2.06 | $-21.10 — $4.26 | $2.4B | ↑0 ↓0 |
| 0y | $13.06 | $-10.65 — $15.90 | $10.1B | ↑0 ↓0 |
| +1q | $3.63 | $2.02 — $4.66 | $2.6B | ↑0 ↓0 |
| +1y | $16.61 | $14.16 — $19.35 | $10.4B | ↑1 ↓0 |
Cross-Platform Signals
No insider trades were reported. Congressional activity includes a small buy by Rep. Gilbert Cisneros (Democrat) and a small sell by Rep. Maria Elvira Salazar (Republican) in early June, which are not significant signals. Institutional changes are mixed: Empowered Funds trimmed 62.4%, while Walleye Capital doubled its position (+2143.7%). Short interest is high at 61% of TRF volume, indicating heavy bearish positioning. This divergence between the analyst upgrade and elevated short interest could create a squeeze scenario if earnings deliver.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access